Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5637
Name pancreatic adenosquamous carcinoma
Definition A pancreatic ductal carcinoma that derives_from squamous cells and gland-like cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic adenosquamous carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04116073 Phase II Retifanlimab INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer Recruiting USA 0
NCT04581343 Phase I Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) Active, not recruiting USA 0
NCT04858334 Phase II Olaparib A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial Recruiting USA 0
NCT04896073 Phase II Minnelide A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) Recruiting USA 0
NCT05209074 Phase I Fluorouracil + Irinotecan + Ivosidenib + Leucovorin + Oxaliplatin Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Not yet recruiting USA 0
NCT05216120 Phase II Pemigatinib Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas Not yet recruiting USA 0
NCT05417386 Phase I Fluorouracil + Irinotecan + Leucovorin + NIS793 + Oxaliplatin Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFIRINOX + NIS793 in Pancreatic Cancer Not yet recruiting USA 0
NCT05419479 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin AB154 + APX005M + Zimberelimab Switch Maintenance in Pancreatic Not yet recruiting USA 0
NCT05440942 Phase I Retifanlimab + Ruxolitinib + Trametinib Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma Not yet recruiting USA 0